Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 107 for “"Anticancer drug"”.
-
Comparison of phenanthriplatin, a novel monofunctional platinum based anticancer drug candidate, with cisplatin, a classic bifunctional anticancer drug
… responsible for removal of platinum-based anticancer drugs. In this study, 146 bp duplexes were prepared containing either a site-specific cisdiammineplatinum( Il)-DNA intrastrand d(GpG) cross-link or a cisdiamminephenanthridinechloroplatinum( Il)-DNA dG adduct. Comparison of the repair …
-
Development and Evaluation of Organometallic Anticancer Drug Candidates
There is an urgent need to find novel anticancer therapeutics with different mechanisms of action than platinum-containing drugs, particularly for patients who relapse after having been initially treated with a platinum-containing chemotherapy regimen. This chemoresistance phenomena, along with the …
-
Development and Evaluation of Organometallic Anticancer Drug Candidates
There is an urgent need to find novel anticancer therapeutics with different mechanisms of action than platinum-containing drugs, particularly for patients who relapse after having been initially treated with a platinum-containing chemotherapy regimen. This chemoresistance phenomena, along with the …
-
Application of HCRSV protein cage for anticancer drug delivery
… virus (HCRSV) was explored as a platform for anticancer drug delivery. PC was prepared by removing viral RNA from coat proteins by dialysis against a Ca2+-deficient buffer of pH 8.0, and reassembling the coat proteins by dialysis with a Ca2+-containing buffer of pH 5.0. Using polyacids and …
-
Turning stealth liposomes into cationic liposomes for anticancer drug delivery
<p>Targeting the anticancer agents selectively to cancer cells is desirable to improve the efficacy and to reduce the side effects of anticancer therapy. Previously reported passive tumor targeting by PEGylated liposomes (stealth liposomes) have resulted in their higher tumor accumulation. However …
-
Human lactate dehydrogenase heterogeneous biocatalyst for efficient anticancer drug screening
L'abstract è presente nell'allegato / the abstract is in the attachment
-
Overcoming toxicity and resistance limitations of the anticancer drug temozolomide
Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2026-12-01
-
Synthetic strategies for the design of platinum anticancer drug candidates
Chapter 1. The Synthetic Chemistry of Platinum Anticancer Agents Since the inception of cisplatin as a clinically approved anticancer agent, a large number of platinum compounds have been synthesized with the aim of finding new, improved drugs. As a result of these efforts, only two additional …
-
Synthesis of triplex-forming oligonucleotide conjugates of the anticancer drug temodal
Covalent attachment of the anticancer drugs temozolomide (Temodal) and mitozolomide to triplex-forming oligonucleotides (TFOs) is a potential way of targeting these alkylating agents to specific gene sequences to maximise site-selectivity. In this work, polypyrimidine TFO conjugates of both drugs …
-
Crystal structure of the anticancer drug cisplatin bound to duplex DNA
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemistry, 1996.
-
Design of Functional Polymeric Micelles as a Carrier for Anticancer Drug Delivery
… nanoparticles are frequently utilized as drug delivery carriers due to their particular core/shell structure, ease of functionalization, sustained circulation in the blood and its ability to passively accumulate in leaky tumor tissues. Two important factors that should be considered in the …
-
PREPARATION AND EVALUATION OF MESOPOROUS SILICA NANOPARTICLES FOR PLATINUM-ACRIDINE ANTICANCER DRUG DELIVERY
… as an inert carrier material in oncology drug formulations. In this dissertation, MSNs were prepared and suitably functionalized to serve as a chemically robust and biocompatible delivery platform for highly cytotoxic platinum-acridine anticancer agents. The first part of the thesis …
-
Design and Synthesis of Doxorubicin Conjugated Gold Nanoparticles as Anticancer Drug Delivery System
… is one of the most widely used and effective anticancer agents to treat a wide spectrum of tumors. But its success in cancer therapy is greatly compromised by its cumulative dose-dependent side effects of cardiotoxicity and tumor cell resistance. For the purpose of addressing these side …
-
Structural and functional consequences of platinum anticancer drug binding to free and nucleosomal DNA
… are three FDA-approved members of the platinum anticancer drug family. These compounds induce apoptosis in tumor cells by binding to nuclear DNA, forming a variety of adducts, and triggering cellular responses, one of which is the inhibition of transcription. The focus of this thesis is on …
-
Transcription and mismatch repair in the mechanism of action of the anticancer drug cisplatin
… or cisplatin) is a powerful cytotoxin and anticancer therapeutic, used most effectively in the treatment of testicular and ovarian cancers. By contrast, the geometric isomer of cisplatin, trans- DDP, is comparatively non-toxic and fails to show significant antitumor activity. Cisplatin is …
-
COMBINATORIAL MOLECULAR PHARMACOLOGICAL AND PRECLINICAL STUDIES OF AN EPIGENETIC ANTICANCER DRUG, 3-DEAZANEPLANOCIN A, IN RATS
… excretion (80.3 % recovered as the unchanged drug by 72 h). DZNep was not extensively metabolized in vivo (86.80 % recovery of DZNep unchanged from urine and feces by 72 h). A unilamellar pegylated liposomal formulation containing DZNep (L-DZNep) was developed using a remote-loading method in …
-
The role of base excision repair proteins in the cellular responses to the anticancer drug cisplatin
Thesis (Ph.D.)--Massachusetts Institute of Technology, Division of Bioengineering and Environmental Health, 2000.
-
Transient receptor potential melastatin member 4 is the executioner protein for anticancer drug-induced necrotic cell death
Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2024-12-01
-
The role of human upstream binding factor hUBF in mediating the cytotoxicity of the anticancer drug cisplatin
Thesis (Ph. D.)--Massachusetts Institute of Technology, Division of Toxicology, 1996.
-
Specific binding of human SRY (Sex-Determining Region Y) to DNA adducts of the anticancer drug cisplatin
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemistry, 1997.
Page 1 of 6